| pubmed-article:17595888 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0470187 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:17595888 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:17595888 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17595888 | pubmed:dateCreated | 2007-6-28 | lld:pubmed |
| pubmed-article:17595888 | pubmed:abstractText | Application-site disorders are well-known adverse events (AEs) associated with subcutaneous (s.c.) injection. With high-dose, high-frequency interferon (IFN)-beta1a (Rebif) these AEs are generally mild but may lead to the discontinuation of some patients. The objective of this study was to compare the safety, tolerability, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of two new formulations of Rebif (Rebif New Formulation: RNF1 and RNF2) with the current formulation (hereafter referred to as R) and placebo. | lld:pubmed |
| pubmed-article:17595888 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17595888 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17595888 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17595888 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17595888 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17595888 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17595888 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17595888 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17595888 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17595888 | pubmed:issn | 0946-1965 | lld:pubmed |
| pubmed-article:17595888 | pubmed:author | pubmed-author:BertoliniGG | lld:pubmed |
| pubmed-article:17595888 | pubmed:author | pubmed-author:PriestleyAA | lld:pubmed |
| pubmed-article:17595888 | pubmed:author | pubmed-author:SeiberlingMM | lld:pubmed |
| pubmed-article:17595888 | pubmed:author | pubmed-author:JaberAA | lld:pubmed |
| pubmed-article:17595888 | pubmed:author | pubmed-author:BrearleyCC | lld:pubmed |
| pubmed-article:17595888 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17595888 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:17595888 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17595888 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17595888 | pubmed:pagination | 307-18 | lld:pubmed |
| pubmed-article:17595888 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:meshHeading | pubmed-meshheading:17595888... | lld:pubmed |
| pubmed-article:17595888 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17595888 | pubmed:articleTitle | Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-beta1a: a double-blind, placebo-controlled comparison with the currently available formulation. | lld:pubmed |
| pubmed-article:17595888 | pubmed:affiliation | Merck Serono International S.A., Geneva, Switzerland. | lld:pubmed |
| pubmed-article:17595888 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17595888 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17595888 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17595888 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
